Bao Y H
307 Hospital, Academy of Military Medical Sciences, Beijing.
Zhonghua Zhong Liu Za Zhi. 1992 Nov;13(6):452-5.
The efficacy of high dose chemotherapy with autologous bone marrow rescue (ABMR) was given to 10 patients with small cell lung cancer (SCLC). Four patients received high dose methotrexate plus ABMR followed by chest irradiation. Six patients giving complete response after induction chemotherapy were given intensive chemotherapy plus ABMR only. The over-all survival of these 10 patients was 30.5 months with a range of 6-96 months. Five of them are surviving as of this writing, 3 survived for more than two years and 2 for more than 5 years. Toxic reactions were not severe. Systemic metastasis was the Leading cause of treatment failure. ABMR was effective and safe. When combined with radiotherapy ABMR could be expected to improve the result of intensive chemotherapy for limited SCLC.
对10例小细胞肺癌(SCLC)患者采用大剂量化疗联合自体骨髓挽救(ABMR)治疗。4例患者接受大剂量甲氨蝶呤联合ABMR,随后进行胸部放疗。6例诱导化疗后完全缓解的患者仅接受强化化疗联合ABMR。这10例患者的总生存期为30.5个月,范围为6至96个月。截至撰写本文时,其中5例仍存活,3例存活超过两年,2例存活超过5年。毒性反应不严重。全身转移是治疗失败的主要原因。ABMR有效且安全。与放疗联合使用时,ABMR有望改善局限期SCLC强化化疗的效果。